-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Epcoritamab, a Novel Subcutaneous Bi-Specific CD3xCD20 Antibody for the Treatment of Patients with B-NHL: From Bench to Bedside and Beyond

Sponsor: Genmab
Program: Product Theaters
Monday, December 7, 2020: 10:30 AM-11:30 AM
Epcoritamab, a Novel Subcutaneous Bi-Specific CD3xCD20 Antibody for the Treatment of Patients with B-NHL: From Bench to Bedside and Beyond

Tahamtan Ahmadi, MD, PhD

Genmab US, Inc, Princeton, NJ
See more of: Product Theaters
<< Previous Product Theater | Next Product Theater >>